Immunovant, Inc. (IMVT)

49.83 +0.94 (+1.92%) At close: 1:00PM EST

Immunovant, Inc.

320 West 37th Street
New York, NY 10018
United States
917 580 3099
http://www.immunovant.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 42

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Peter Salzmann M.B.A., M.D.	CEO & Director	1.09M	N/A	1967
Ms. Pamela Yanchik Connealy M.B.A.	Chief Financial Officer	544.84k	N/A	1962
Dr. Julia G. Butchko Ph.D.	Chief Devel. & Technology Officer	N/A	N/A	1971
Dr. Michael J. Elliott MBBS, Ph.D.	Chief Scientific Officer	N/A	N/A	1959
Dr. Alan Jacobs M.D.	VP & Head of Neurology Devel.	N/A	N/A	N/A
Dr. Ann M. Daus	VP & Head of Global Quality	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Corporate Governance

Immunovant, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.